Melatonin improves sleep quality in hemodialysis patients

• Main Authors: M Edalat-Nejad, F Haqhverdi, T Hossein-Tabar, M Ahmadian
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2013-01-01
• Series: Indian Journal of Nephrology
• Subjects: End-stage renal disease; hemodialysis; melatonin; pittsburgh sleep quality index; sleep
• Online Access: http://www.indianjnephrol.org/article.asp?issn=0971-4065;year=2013;volume=23;issue=4;spage=264;epage=269;aulast=Edalat-Nejad

Disturbed sleep is common in end-stage renal disease (ESRD). Exogenous melatonin has somniferous properties in normal subjects and can improve sleep quality (SQ) in several clinical conditions. Recent studies have shown that melatonin may play a role in improving sleep in patients undergoing dialysis. The goal of the present study was to assess the effect of exogenous melatonin administration on SQ improvement in daytime hemodialysis patients. Lipid profile and the required dose of erythropoietin (EPO) are also reported as secondary outcomes. In a 6-week randomized, double-blind cross-over clinical trial, 3 mg melatonin or placebo was administered to 68 patients at bedtime. A 72-h washout preceded the switch from melatonin to placebo, or vice versa. SQ was assessed by the Pittsburgh sleep quality index (PSQI). Sixty-eight patients completed the study protocol and were included in the final analysis. Melatonin treatment significantly improved the global PSQI scores ( P < 0.001), particularly subjective SQ ( P < 0.001), sleep efficiency ( P = 0.005) and sleep duration ( P < 0.001). No differences in sleep latency and daytime sleepiness were observed. Melatonin also increased the high-density lipoprotein (HDL) cholesterol ( P = 0.003). The need for EPO prescription decreased after melatonin treatment ( P < 0.001). We conclude that melatonin can improve sleep in ESRD. The modest increase in HDL cholesterol and decrease in the EPO requirement are other benefits associated with this treatment